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Abstract
The use of spectrophotometry for the analysis of the cerebrospinal
ﬂuid (CSF) is reviewed. The clinically relevant CSF pigments — oxy-
hemoglobin and bilirubin — are introduced and discussed with re-
gard to clinical differential diagnosis and potentially confounding vari-
ables (the four “T”s or: traumatic tap, timing, total protein and total
bilirubin). The practical laboratory aspects of spectrophotometry and
automated techniques are presented in the context of analytical and
clinical speciﬁcity and sensitivity. The perceptual limitations of human
color vision are highlighted and the use of visual assessment of the
CSF is discouraged in light of recent evidence from a national audit in
the United Kingdom. Finally, future perspectives including the need
for longitudinal CSF proﬁling and routine spectrophotometric calibra-
tion are outlined.
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21 Introduction
Patient management decisions in medicine depend to an ever increas-
ing degree on objective — evidence based — diagnostic guidelines. This
is particularly true for neurocritical care where many patients are uncon-
scious or unable to communicate adequately. Therefore, the diagnostic
procedures underlying the guidelines must not only be correctly applied,
but must also be legally and scientiﬁcally testable, to justify the manage-
ment decisions.
Recently, concern has been raised that about 99% of over 3,000 labo-
ratories participating in two independent US surveys1,2 relied on visual as-
sessment of the cerebrospinal ﬂuid (CSF) for xanthochromia (Greek for “of
yellow color”). Xanthochromia assessment is used to help decide whether
or not an intracranial bleed has occurred, which is important for diagnosing
a subarachnoid hemorrhage (SAH). Because a SAH is associated with a
high mortality (50–60%), which increases signiﬁcantly (to about 80%) if the
initial diagnosis is missed and a rebleed occurs, a meticulous diagnostic
approach is essential for rapid and appropriate treatment.
In this review, we argue for abandoning the visual assessment of the
CSF for xanthochromia, because new evidence suggests that it is percep-
tually impossible or unreliable in about 80% of critical cases.3,4 Instead, we
argue for relying on the more sensitive and more speciﬁc spectrophotom-
etry,5 which is also documentable and therefore legally testable. Firstly,
we review the clinical relevance of CSF pigment analysis. Secondly, we
3summarize why the human visual system is unreliable for detecting xan-
thochromia. Thirdly, we review the laboratory techniques available for CSF
analysis. Fourthly, we review the UK experience with spectrophotometric–
based national guidelines and the current US recommendations for CSF
pigment analysis. We conclude with an evidence based diagnostic ﬂow–
chart.
2 The clinical relevance of CSF pigment analy-
sis
The normal CSF is clear and colorless, as shown by the roughly ﬂat spec-
trophotometric trace depicted in Figure 1A. It consists of 99% water and
has a much lower protein concentration ( 350 mg/L) than the serum
(70,000 mg/L). The color changes when additional substances such as
bilirubin (yellow) or hemoglobin (red) enter the CSF. The correct identi-
ﬁcation of CSF pigments allows one to draw pertinent conclusions about
pathology in the patient under examination. Although the major concern for
the neurocritical care physician will be to correctly identify SAH, there are
confounding factors and other conditions that need to be considered when
making the diagnosis (for review see reference6 and references therein).
The color changes associated with blood pigments released into the
CSF, as the result of potentially life threatening conditions such as an
aneurysmal SAH, are very rapid. Erythrocytes are haemolysed and re-
lease Hb (red colored) which dissociates into heme and globin. The heme
4groups are, in turn, converted by heme oxygenase to biliverdin (bile green)
and further by biliverdin reductase to bilirubin (canary yellow).7 Bilirubin
arises only in vivo which makes it the most speciﬁc metabolite for dis-
tinguishing a true bleed from a traumatic tap.7–14 In fact, the presence of
bilirubin in the CSF taken 6–12 hours after ictus in a patient with suspected
SAH is virtually a fail–proof diagnostic.9,12,15,16
2.1 Subarachnoid hemorrhage (SAH)
Cerebral aneurysms are estimated to be present in about 5,000,000 North
Americans of whom approximately 30,000 are likely to experience an aneurys-
mal SAH.17,18 For these the mortality from a SAH rises to about 80% if
a rebleed occurs.19 The risk of a rebleed can be minimized by protec-
tion of the aneurysm either surgically (“clipping”) or radiologically (“coil-
ing”).19,20 Clearly, sensitive diagnostic tools are crucial for determining if an
aneurysmal hemorrhage has occurred and to enable rapid and adequate
patient management. At present the diagnosis of a SAH is predominantly
made on the basis of non–enhancing computerized tomography (CT) of
the brain.6,19 There are, however, two situations under which the CT can
be unreliable. Firstly, it may occur when the CT is performed some time af-
ter the bleed; Van Gjin et al. reported that the sensitivity of the CT falls from
97% in the ﬁrst day after the bleed to less than 10% after three weeks.21
Others have reported a negative CT in 14.6–20% of patients with a proven
SAH,22,23 which presumably must also be due in part to lack of prompt
5scanning. Secondly, a caudally–located bleed or small bleed adjacent to
bony structures (i.e. above the orbits) can be difﬁcult to detect because of
imaging artifacts. Thirdly, the scan may be suboptimal technically; beeing
difﬁcult due to severe anaemia or movement artefacts.6 Even when opti-
mally timed, using modern scanners and in the best of hands the CT still
has a false negative rate of approximately 2-3% and conﬁdence intervals
are wide.24,25 Not surprisingly, therefore, a body of literature provides ev-
idence for the presence of a SAH by CSF analysis for xanthochromia in
cases where the CT scan was negative.15,16,23,24,26–29 In the future, MRI
may be helpful in selected cases. There is preliminary evidence that its
sensitivity is increased for detecting a bleed two to three weeks following a
SAH.30,31 Different sequences have been used with varying success, but
more data are needed to recognize their potential pittfalls and their false
positive and negative rates.30–36 It would be important to compare the ac-
curacy of the various MRI techniques with that of rigorous CSF analysis
as outlined in this review.
2.2 The traumatic tap
The ﬁrst traumatic tap was documented by Quincke on the 23rd of July
1891 whilst performing the fourth consecutive lumbar puncture (LP) in a
7 year old girl with hydrocephalus.37 Overall a traumatic tap with a sig-
niﬁcant amount of blood can be expected in about 14–20% of standard
LPs.8,24,38,39 Importantly, this ﬁgure increases to 72% if a traumatic tap is
6deﬁned by an erythrocyte count of at least 100 cells (per L, or  106/L) in
the sample.38 There is no consensus about the precise deﬁnition of a trau-
matic tap. A pragmatic cut–off appears to be 400  106 erythrocytes/L.8,24
A traumatic tap causes contamination of the CSF sample with erythro-
cytes, possibly by puncture of the venous plexuses within the spinal sac or
vessels adjacent to the cauda equina.8 The recommendations for a correct
lumbar tap are to collect four consecutive samples and use the last one for
spectrophotometry. The samples should be transported to the laboratory
as quickly as possible in order to minimize the risk of in vitro haemolysis
of any erythrocytes. Only the last one should be used for assessment of
CSF pigments and it should be centrifuged at 2000 rpm for 5 minutes.
The supernatant should then be taken for spectrophotometric analysis as
described below.
It is technically impossible to exclude that some erythrocytes may have
haemolysed. Collecting multiple fractions helps reduce this problem. In
the worst case scenario, if a traumatic tap has occurred and all the CSF
is collected in one tube and the sample reaches the laboratory after a sig-
niﬁcant delay, then making a visual assessment for xanthochromia will be
impossible as explained below. If this occurs, a spectrophotometric scan
as shown in Figure 1 (B) may be observed. This scan provides evidence
for the presence of oxyhemoglobin in the CSF, but not for bilirubin as no
peak is seen at 455 nm ∗.
The absorption maxima for bilirubin in the visible light is around 455 nm. The UK
guidelines however recommend measuring the absorbance at 476 nm where the absorp-
7Fluid from a LP which is, in fact a traumatic tap, when performed at
least 12 hours after a SAH can still be used, because the presence of a
peak at 476 nm (bilirubin) will still be indicative of SAH. For an example of
this situation see Figure 1 (C). A similar scan may be expected if a second
LP is performed subsequent to a traumatic tap but over 12 hours after
ictus.
It is important to wait at least 12 hours after ictus before performing the
LP to allow time for a sufﬁcient conversion of heme to bilirubin to occur. A
traumatic tap taken too early after ictus however precludes the option of
a follow–up LP because any erythrocytes released into the lumbar sac as
a consequence of the traumatic tap will subsequently lyse and may give
rise to a spectrophotometric scan indistinguishable from that of a SAH
(Figure 1 C).
It is perceptually impossible to see by eye a small amount of bilirubin
in the presence of a large amount of haemolysed erythrocytes (red).40
Hence, visual assessment of xanthochromia in the context of a traumatic
tap is unreliable, as reported previously.41,42
2.3 The size of the problem
Currently about 30% of SAH patients are misdiagnosed at their initial visit.6
Based on the above mentioned estimates17,18 this would affect about 9,000
of those 30,000 patients who suffer from a SAH per year in North Amer-
tion curves for oxyhemoglobin and bilirubin are better separated.
8ica alone. Optimal use of diagnostic tools may improve this percentage.
However, given a false negative CT rate of approximately 2-3% with mod-
ern scanners,24 up to 900 critical patients may be missed even in the best
equipped specialist units. Thus, the real number is likely to be higher.
These cases may proﬁt from a LP, of which about 126 (12-14%) may be
expected to turn into a traumatic tap; making the visual assessment ex-
tremely difﬁcult or impossible.8,24,38,39 In view of the perceptional limita-
tions of human color vision, with an estimated 80% of critical samples not
being seen as yellow,3 CSF spectrophotometry would be helpful in diag-
nosing those 9,000 patients who are expected to bleed per year and es-
sential for those 900 who are expected to have a “false negative” normal
CT scan.
3 Human Color Vision and the Limitations of
Visual Assessment
Under good viewing conditions, the human eye can discriminate about
150 wavelengths in the visible spectrum,43,44 and as many as 20,000 non-
spectral hues.45 This ability depends upon comparisons of the differen-
tial photon absorptions by the three types of retinal photoreceptor cells,
each containing a different photopigment: the short (S)-, middle (M)- and
long (L)- wavelength sensitive cones. The absorbance spectra of the S-,
M- and L-cones overlap considerably, but have their wavelengths of max-
imum absorbance in different parts of the visible spectrum; ca. 440, 545
9and 556 nm, respectively, when estimated in vivo.46 Although the proba-
bility that a photon will be absorbed by a given cone photoreceptor varies
by many orders of magnitude with wavelength, once it is absorbed its ef-
fect is independent of wavelength. Thus, the individual cones are blind to
the wavelength of capture; they only signal the rate at which photons are
caught.
These physiological facts impose severe constraints on the visual as-
sessment of CSF for xanthochromia. In fact, CSF samples of different
spectral distributions, will appear visually identical, if they produce the
same absorptions in the three different types of cone photoreceptors, and
only different, if they do not.
3.1 Sensitivity of human colour vision
The concentration of bilirubin in an otherwise colorless CSF solution must
exceed a certain threshold in terms of excitation purity† in order for it to be
detected by xanthochromia. From earlier studies, we estimate that the hu-
man visual threshold lies at approximately 2.4% excitation purity; whereas
spectrophotometry is reliably capable of detecting concentrations of biliru-
bin that produce excitation purities as low as 0.62%.
Our results are consistent with the raw data provided by Linn et al. who
compared visual inspection with spectrophotometry for detecting low con-
yThe excitation purity can be calculated from the spectrophotometric trace with re-
spect to the viewing illuminant (usually daylight or a tungsten source) by using standard
colorimetric procedures, which have been established by the Commission Internationale
de l’´ Eclairage (CIE, or the International Commission on Illumination).3,40
10centrations of bilirubin in the CSF.47 Linn et al. spiked clear human CSF
with different concentrations of bilirubin. The extinction was determined
at 450-460 nm. Their subjects were required to assign the CSF samples
visually to one of three categories: “yellow”, “colorless” or “doubtful”. Spec-
trophotometry, used as the gold standard, was capable of detecting a trace
of bilirubin in samples with an extinction as low as 0.01; whereas human
observers could not perform reliably below an extinction of 0.06 (see Ta-
ble 2 ‡).47 It would be interesting to analyse the original absorption spectra
of Linn et al.47 to determine whether their visual threshold (extinction of
0.06) corresponds to ours (excitation purity of about 2.4%).40
3.2 Speciﬁcity of human colour vision
Any CSF sample will be perceived as having only a single hue or domi-
nant wavelength regardless of how many wavelengths§ actually comprise
its spectral distribution. In other words, although the human visual sys-
tem is easily capable of discriminating between the hues of different CSF
samples, provided that the samples produce signiﬁcantly different photon
catches in the three cone classes, it is incapable of differentiating between
the composite wavelengths within any given sample.
zFor comparison with our results, we only included the observed frequencies of their
samples seen as “yellow” or as “colorless” in Table 2. Samples for which no decision
could be made because the visual inspection was “doubtful” are not included into our
post–hoc analysis.
xThe dominant wavelength can be calculated from the spectrophotometric trace with
respect to the viewing illuminant (usually daylight or a tungsten source) by using standard
colorimetric procedures, which have been established by the Commission Internationale
de l’´ Eclairage (CIE, or the International Commission on Illumination).3,40
11Thus, a CSF sample containing bilirubin, which absorbs in the blue part
of the spectrum and transmits in the yellow, may not appear xanthochromic
or yellow, if the bilirubin concentration is low or if its concentration is ex-
ceeded by that of another pigment, such as oxyhemoglobin, which has
characteristic absorbance signatures in other parts of the spectrum (e.g.
red) to which the eye is sensitive. We have shown elsewhere3,40 that as
many as 80% of CSF samples containing substantial amounts of bilirubin
may not be perceived as being xanthochromic. The presence of bilirubin
therefore cannot reliably be ruled out in cases where CSF is visibly red.
3.3 Color vision is unreliable for detecting CSF pigments
In short, human vision is an unreliable or inappropriate means of assess-
ing a CSF sample for the presence of bilirubin; not because the eye is
insensitive to wavelength, but rather because it cannot differentiate quanti-
tatively between the constituent absorbances determining the overall color
appearance of the CSF sample. In contrast, spectrophotometry is speciﬁ-
cally designed to do this job.
3.4 Other situations in which the CSF appears yellow
(xanthochromic) to the eyes
There are a number of conditions and drugs which can give the CSF a
yellowish appearance (Table 1). For clinical practice, a high total protein
concentration is possibly the most relevant factor because it occurs in a
broad spectrum of acute neurological disorders. Some of these, such as
12acute encephalitis and meningitis, share clinical features (i.e. headache,
meningism, etc.) with SAH.6
4 The laboratory analysis of CSF pigments
A number of laboratory techniques are available for measuring CSF pig-
ments. Spectrophotometry is preferred because it allows the simultaneous




Each material has its speciﬁc color when viewed in white light because cer-
tain wavelengths are absorbed. Thus, a ﬂuid containing a substance that
absorbs blue light (< 466 nm4) will appear yellow, when transluminated by
white light, because only red and green light are being transmitted.
Spectrophotometry is a technique that measures the amount of light
being transmitted at each wavelength. In a laboratory context, however,
one refers to the absorbance rather than the transmittance at each wave-
length; with absorbance being the inverse of transmittance. Confusion can
be avoided by remembering that bilirubin which absorbs in the blue part of
the spectrum (455 nm) will typically be perceived as yellow.
All haem proteins exhibit their maximal absorbance in the Sor´ et band
region of 400 to 440 nm (thus they tend to appear yellow). Additional,
13smaller peaks are seen between 500 and 600 nm.
4.1.2 Bilirubin
The key biochemical mechanism that makes CSF analysis such a useful
diagnostic tool is the conversion of hemoglobin (Hb) to bilirubin, which can
be easily detected by spectrophotometry. Essentially the erythrocytes re-
leased by the bleed into the CSF haemolyse. In vitro experiments show
that haemolysis starts about 30 minutes after transfer of autologous red
cells into CSF. Given the long half–life of about 120 days of erythrocytes
in vivo, it is likely that the process starts by the early haemolysis of older
and more fragile erythrocytes. Haemolysis leads to the release of Hb and
oxyhemoglobin into the CSF. Figure 1 (B) shows the typical spectrophoto-
metric curve of Hb and oxyhemoglobin. Clinical experience indicates that
it takes about 12 hours to produce the critical amount of bilirubin in vivo
required to become detectable by spectrophotometry.
The typical spectrophotometric scan of a CSF sample from a patient
with proven SAH is shown in Figure 1 (C). The peak at 415 nm is the
main peak indicating the presence of oxyhemoglobin or Hb in the CSF
sample, with two secondary peaks between 500 to 600 nm¶. The broad
absorbance shoulder band at the right handside of the Hb peak is bilirubin.
{If these secondary peaks are absent then the ﬁrst peak is likely to be caused by Hb
alone.
144.1.3 Efﬁcacy of spectrophotometry
The value of using spectrophotometry in the diagnosis of SAH as opposed
to the widely practiced visual assessment for xanthochromia is probably
best illustrated by a retrospective analysis of a scientiﬁc exchange that
took place between 1988 and 1989. MacDonald and Mendlow reported
that 46% of 68 SAH patients had a bloodstained, but not a xanthochromic
CSF, on the basis of visual assessment. Accordingly, they concluded that
a bloodstained but not xanthochromic CSF is the most sensitive sign of
SAH.23 This conclusion was immediately contested by Vermeulen et al.
who pointed out that xanthochromia was present in 100% of samples
taken between 12 hours to 2 weeks from the ictus.15 What MacDonald
and Mendlow, in fact experienced was that visual assessment of the CSF
did not allow them to perceive the presence of bilirubin (yellow) in those
46% of samples that were bloodstained. It needs to be borne in mind that
this was a retrospective study of patients with an angiographically con-
ﬁrmed aneurysmal SAH. Our own retrospective study of 632 CSF sam-
ples revealed that in about 80% of critical cases the color of the sample
fell outside the hue category that would be perceived as yellow.3,4 This is
consistent with previous studies14,41,42,48 and reinforces the point made by
Vermeulen et al. that spectrophotometric assessment of the CSF should
be the analytical method of choice.15
154.1.4 How to do it
The UK National Guidelines for analysis of CSF for bilirubin in suspected
SAH give detailed instructions about sample acquisition, handling, analy-
sis and interpretation of the results.9 In brief, these are:
 Ideally take 4 sequential CSF samples with a time delay of at least
12 hours from ictus. Only the last one is to be used for spectropho-
tometry. Measurement of the plasma bilirubin level at the time of LP
is advised.
 Transport sample as soon as possible to the laboratory, avoiding un-
due mechanical haemolysis (i.e. shaking, or delivery through a pneu-
matic tube system) and excessive light exposure.
 Centrifuge sample at >2000 rpm for 5 minutes after receipt in the
laboratory and store supernatant at 4◦ C.
 Water (H2O) is used as a blank and the undiluted supernatant is used
for a zero–order spectrophotometric scan (350–750 nm). A cuvette
with a 1-cm path length is recommended . Examples of such scans
are shown in Figures 1 (A–B).
 Draw a baseline (see Figure 2) and measure the distance from the
baseline to the scan at 476 nm, which is deﬁned as the net biliru-
kSmall volumes (minimum of 50L) can be measured using disposable cuvettes. For
safety reasons we do not recommend the use of 10L cuvettes, because they are difﬁcult
to clean after the handling of infectious material. About 1000L of sample is required for
a standard cuvette.
16bin absorbance (NBA)∗∗. Concurrently, the net oxyhemoglobin ab-
sorbance (NOA) should be measured at its highest peak between
410–418 nm.
 The interpretation is based on the simple combination of the AU for
NBA and NOA, if the serum bilirubin is <20 mol/L and the CSF total
protein <1.0 g/L. Accordingly, there are three possible outcomes:
1. No evidence to support SAH. NBA 0.023 AU and NOA =0 AU;
2. SAH cannot be excluded, but the predictive value of the test is
low. NBA 0.023 AU and 0< NOA 0.1 AU (if NOA 0.1 AU
a small increase of bilirubin may be masked. This may occur if
the LP is performed too early.);
3. The results are consistent with SAH. (A) NBA >0.023 AU and
NOA =0 (i.e., seen one week after SAH), (B) NBA >0.023 AU
and 0< NOA 0.1 AU or NOA 0.1 AU (i.e., seen early after the
SAH, or if a traumatic tap was performed with an appropriate
time delay from the SAH, or a rebleed has occurred and the LP
was performed directly after this complication).
 In the presence of a serum bilirubin 20 mol/L or a CSF total protein
>1.0 g/L additional calculations as outlined in the UK guidelines are
For a straight forward absorbance a value of >0.023 absorbance units (AU) is taken
as recommended by Vermeulen and colleagues.15 The corrected value takes the plasma
bilirubin levels alongside the total protein levels of the CSF and serum into account and
refers to values of >0.007 AU, as explained elsewhere.9,49,50 For simplicity we refer to
the uncorrected value in this review.
17recommended.9
A simpliﬁed diagnostic ﬂow–chart is shown in Figure 3.
4.2 Automated measurements
Ungerer and colleagues reported an automated method for measuring
CSF bilirubin, which is based on the classical Jendrsik-Gr´ of principle which
utilizes the reaction of bilirubin with diazotised sulfanilic acid to yield blue–
green coloured azobilirubin.51 The authors modiﬁed their routine serum
bilirubin assay51,52 and the results were compared with those obtained by
spectrophotometry as outlined in the UK guidelines.9 The intra–assay CV
was 20% for bilirubin concentrations at 100 nmol/L and the detection limit
was 35 nmol/L. The two methods seem to yield a comparable diagnos-
tic performance for samples with a signiﬁcant increase of CSF bilirubin
levels. However, for small amounts of bilirubin, this may not necessarily
be the case, because the reported upper reference limit of the automated
method is over 2-fold higher (359 nmol/L) than the one deﬁned by the UK
NEQUAS (166 nmol/L, corresponding to a corrected absorbance of 0.007
at 476 nm)††.
If validated this method may be of use to those laboratories that do not
have access to a spectrophotometer. It should be borne in mind that the
sample volume required will depend on the dead space of the particular
system and may be large.
yyThe values were taken from the study by Unger et al.,51 but the interpretation on
sensitivity is our own.
185 Guidelines for spectrophotometric analysis
of CSF pigments
5.1 The UK experience
The UK guidelines were published in 2003 by the UK National External
Quality Assessment Scheme (NEQAS) for the Immunochemistry Work-
ing Group, of which one of the authors is a member (GK).9 The effect
that these guidelines had on laboratory practice in the UK was evaluated
through UK–NEQAS over the following year.53 The results revealed that
the implementation of the guidelines had a major impact on clinical prac-
tice in the UK. Prior to the publication of the guidelines, 77/101 (76%) of
laboratories used spectrophotometry as opposed to visual inspection. But
thereafter, the proportion using spectrophotometry increased signiﬁcantly
to 108/115 (94%). Moreover, the approximated error rate decreased from
40% to 9%.
5.2 The US recommendations
At the time of this review, neither the American Academy of Neurology
(AAN) nor the American Neurology Association (ANA) provide advice on
the CSF analysis for xanthochromia. At present, there are no national US
guidelines.
A recent US survey by Edlow and colleagues revealed that a large num-
ber of laboratories evaluate CSF for xanthochromia (1944/2551, 76.2%).1
Of these, 91.8% report routinely on xanthochromia. An impressive 87.4%
19of laboratories achieved a turnaround time of  60 minutes and 97.3%
offered the test 24 hours a day, 7 days a week. However, the analyti-
cal method chosen by 99.7% of the participating laboratories was visual
inspection. This ﬁgure is comparable to that reported in an independent
survey.2 An algorithm for evaluation of possible SAH was proposed [8, Fig-
ure 2] and advice for the CSF analysis was given by these authors on the
“real life” basis that most US laboratories do not presently perform spec-
trophotometry.8
5.3 Future perspectives
CSF bilirubin A longitudinal proﬁle of the bilirubin levels in patients with
SAH is needed. This would allow one to establish the time–frame during
which CSF analysis for bilirubin is reliable. Because bilirubin is metabo-
lized, it is expected that after a certain time has elapsed no bilirubin will be
detectable in the CSF. The study by Vermeulen et al. suggests that, after
2 weeks, 32/32 (100%) of patients still have traces of bilirubin in their CSF.
After 3 weeks, this falls to 20/22 (91%) and after 4 weeks to 10/14 (71%).15
The decrease of CSF bilirubin is likely to depend on the initial blood load,
which is not known in the Vermeulen et al. study. A conservative study
should include patients with only a small amount of blood visible on CT
(i.e., a Fischer grade II).54
CSF oxyhemoglobin A longitudinal proﬁle for oxyhemoglobin after SAH
may also be relevant. Our own quantitative data indicate a secondary
20increase of CSF oxyhemoglobin between days 5 and 6 in 10 patients with
aneurysmal SAH.55 This result was consistent with an animal study by
Pluta et al.56 However, because we did not perform re–imaging, it remains
unknown whether the mild secondary increase of CSF oxyhemoglobin was
due to micro–rebleeds.
Spectrophotometer calibration It is important to ensure that the spec-
trophotometers performing the CSF sample analysis are regularly cali-
brated. Ideally this should be managed through an external quality control
body such as UK–NEQAS. Typically, holmium oxide is used to calibrate
the wavelength response of spectrophotometers. For practical reasons
holmium oxide is dissolved in perchloric acid. Holmium (Ho–165) is a sta-
ble rare earth, discovered by the same J.L. Sor´ et (1878) who gave his
name to the Sor´ et–band (see above). A 4% solution of Holmium Oxide in
10% perchloric acid has 14 peaks at the following wavelengths: 241.08,
249.98, 278.03, 287.47, 333.40, 345.49, 361.16, 358.86, 416.62, 451.24,
467.94, 485.33, 536.97 and 640.84 nm.
Quantitative techniques CSF spectrophotometry is semi–quantitative.57
A range of more quantitative techniques based on derivate spectropho-
tometry have been described.58–60 These techniques may be relevant for
determining the longitudinal proﬁle of CSF bilirubin as proposed above.
21Timing of lumbar puncture The conversion of heme to bilirubin starts
immediately after the haemoylsis of the erythrocytes. The current UK
guidelines advice waiting about 12 hours after ictus to allow for a sufﬁ-
cient quantity of heme be converted into bilirubin.9 Across the world, how-
ever, there are considerable differences in speed of patient management.
In certain situations, it may be difﬁcult or contrary to accepted medical
emergency practice to wait for 12 hours. From a clinical point of view
there are two important scenarios. Firstly, a patient may present with an-
tecedent symptoms prior to ictus that may already have been owing to a
small degree of aneurysmal hemorrhage, a so–called “warning” bleed.6,61
An earlier LP in such patients may be considered, based on the assump-
tion that a sufﬁcient amount of bilirubin (or ferritin as discussed below) is
already present. There are no published studies directly examining this
point, but, if veriﬁed, its application would potentially have important man-
agement implications because such patients may be more vulnerable to
vasospasm. Typically, vasospasm appears not earlier than 3-4 days after
ictus.62,63 However, very occasionally vasospasm is observed before that.
It should be investigated whether or not the presence of bilirubin in the
CSF of patients with sentinel symptoms, possibly due to an earlier warn-
ing bleed may help to identify those at higher risk for vasospasm during
or following angiography, coiling and clipping. The results of such studies
could potentially have management implications.
Secondly, a patient may be admitted with a clinical presentation that
22is suspiciously indicative of a SAH, but with no sentinel symptoms, and a
negative CT brain scan. It seems probable that the use of highly sensi-
tive, quantitative techniques58–60 may permit one to detect small amounts
bilirubin at an earlier time; allowing for a laboratory diagnosis. However,
no data are yet available on early LPs; unfortunately, preventing any state-
ment about the expected levels of bilirubin within the ﬁrst 12 hours after
a bleed. Thus, given the lack of data and the risk that a traumatic tap
may hinder a later, more adequately timed LP, such practice cannot be
recommended at present. In such cases, if there is a high clinical suspi-
cion of a SAH, it may be more appropriate to perform magnetic resonance
angiography or conventional angiography.
CSF ferritin Keir et al. noted that high CSF ferritin levels were detected
in 14 patients who had no evidence for xanthochromia (Tables 2 & 3 in
reference64); ﬁve of whom suffered from an intracranial bleed. In fact, we
routinely use CSF ferritin as a biomarker for an occult bleed. Because the
need for ferritin arises downstream from the metabolism of bilirubin, CSF
ferritin may be detectable for a longer period following a SAH than bilirubin.
It should be noted that high CSF levels of ferritin are unlikely to be speciﬁc
for SAH because they have also been associated with intraparenchymal
cerebrovascular events, miscellaneous central nervous system infections
and vasculitis.65–68
236 Summary
The relevance of CSF pigment analysis was reviewed and its clinical and
diagnostic pitfalls were discussed (The 4 “T”s in Figure 3). The physi-
ological basis for the limitations of human color vision for CSF analysis
was presented. The different practical aspects of spectrophotometry as
the analytical method of choice were reviewed in detail. Special attention
was given to published guidelines and their impact on clinical practise and
pertinent questions to be addressed in future studies were presented.
Finally, the use of the term “xanthochromia” is to be discouraged. Rather,
it is recommended that the clinician should ask for a “CSF pigment anal-
ysis”. The laboratory should use spectrophotometry to evaluate the pres-
ence of CSF pigments such as bilirubin and oxyhemoglobin.
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Contamination with betadine or iodine (i.e.
during surgery)
High CSF total protein
High systemic bilirubin
Other sources of a bleed in the neuroxis
(i.e. haemosiderosis)
Rifampicin
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Figure 1: Examples for (A) a spectrophotometric scan showing a nor-
mal CSF. (B) a spectrophotometric scan showing the presence of oxyhe-
moglobin in the CSF. The highest peak for oxyhemoglobin is observed at
415 nm and secondary, much smaller peaks are observed between 525–
600 nm. (C) a spectrophotometric scan showing the presence of bilirubin
and oxyhemoglobin in the CSF. This scan is consistent with a SAH. For
practical reasons the absorbance for bilirubin will be read at 476 nm, which
is outside the absorbance for oxyhemoglobin. It should be noted that the
maximum of the broad bilirubin broad peak lies within 450–460 nm.Figure 2: An example of “how to” calculate the absorbance (AU) of biliru-
bin. A baseline is drawn from the beginning of the scan at 300 nm to the
bottom deﬂection at about 510 nm. The distance from this baseline to the
scan is measured at 476 nm to obtain the net bilirubin absorbance (NBA).
In this example, which represents an enlarged view of Figure 1 (C), a NBA
of 0.11 AU is calculated. For illustration, the line drawn to determine the
NBA is also demonstrated in the bottom left corner of the graph.Figure 3: A diagnostic ﬂow–chart for assessment of a patient with sus-
pected SAH. CT = non–enhancing computed tomography of the brain,
CSF = cerebrospinal ﬂuid, MRA = magnetic resonance angiography, SAH
= subarachnoid hemorrhage.